Across several neurological conditions, important damage can begin before symptoms fully appear. In multiple sclerosis, PAD2-driven changes to myelin basic protein may weaken myelin and make it more visible to the immune system, helping explain early myelin instability. In ALS, targeting PGAM5, a regulator of mitochondrial stress, slowed progression and helped preserve the nerve-muscle connections needed for movement in preclinical models.
A third study shows how UDCA may reduce stroke-related injury after blood flow returns by activating ALDH3A1, an enzyme that limits harmful lipid damage, oxidative stress, and ferroptosis. Together, these papers point to a shared theme: neurological damage is often shaped by early molecular stress affecting myelin, mitochondria, or cell survival. Understanding these pathways could guide more targeted ways to protect the nervous system before damage becomes harder to reverse.
1. PAD2-mediated citrullination of MBP and early myelin destabilization in multiple sclerosis
Researchers highlight how PAD2-driven changes to myelin proteins may weaken myelin structure and increase immune recognition, potentially contributing to some of the earliest stages of multiple sclerosis.
2. Targeting PGAM5-driven mitochondrial integrated stress response slows ALS progression across subtypes
Targeting the mitochondrial stress regulator PGAM5 slowed disease progression, preserved neuromuscular connections, and improved motor function across multiple ALS subtypes in preclinical models.
3. Ursodeoxycholic acid mitigates cerebral ischemia/reperfusion injury by inhibiting thrombin-induced lipid peroxidation through activation of ALDH3A1
UDCA helped reduce stroke-related brain injury by activating ALDH3A1, a protective enzyme that limits lipid peroxidation, oxidative stress, and ferroptosis. This pathway may support healthier neuronal function after ischemic stroke.
If you’d like to stay informed of the latest publications and breakthroughs in neuron regeneration, join our email newsletter to the right (or below on mobile). We send out weekly updates with the latest papers and studies, as well as podcast episodes with the people driving Neuroregenerative breakthroughs.
